ESCITALOPRAM OXALATE Drug Patent Profile
✉ Email this page to a colleague
When do Escitalopram Oxalate patents expire, and what generic alternatives are available?
Escitalopram Oxalate is a drug marketed by Mylan Pharms Inc, Amneal Pharms, Antrim Pharms Llc, Aurobindo Pharma Ltd, Chartwell Molecular, Hetero Labs Ltd Iii, Macleods Pharms Ltd, Taro, Accord Hlthcare, Chartwell Rx, Dash Pharms, Graviti Pharms, Hikma Pharms, Invagen Pharms, Jubilant Cadista, Pharm Assoc, Prinston Inc, Teva Pharms Usa, Torrent Pharms Ltd, and Zydus Lifesciences. and is included in twenty-three NDAs.
The generic ingredient in ESCITALOPRAM OXALATE is escitalopram oxalate. There are twenty-six drug master file entries for this compound. Fifty-one suppliers are listed for this compound. Additional details are available on the escitalopram oxalate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Escitalopram Oxalate
A generic version of ESCITALOPRAM OXALATE was approved as escitalopram oxalate by AMNEAL PHARMS on March 14th, 2012.
Summary for ESCITALOPRAM OXALATE
US Patents: | 0 |
Applicants: | 20 |
NDAs: | 23 |
Finished Product Suppliers / Packagers: | 50 |
Raw Ingredient (Bulk) Api Vendors: | 91 |
Clinical Trials: | 21 |
Patent Applications: | 660 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for ESCITALOPRAM OXALATE |
Drug Sales Revenues: | Drug sales revenues for ESCITALOPRAM OXALATE |
What excipients (inactive ingredients) are in ESCITALOPRAM OXALATE? | ESCITALOPRAM OXALATE excipients list |
DailyMed Link: | ESCITALOPRAM OXALATE at DailyMed |
Recent Clinical Trials for ESCITALOPRAM OXALATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Sultan Qaboos University | Phase 4 |
NYU Langone Health | Phase 4 |
National Institute on Aging (NIA) | Phase 4 |
Pharmacology for ESCITALOPRAM OXALATE
Drug Class | Serotonin Reuptake Inhibitor |
Mechanism of Action | Serotonin Uptake Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for ESCITALOPRAM OXALATE
Paragraph IV (Patent) Challenges for ESCITALOPRAM OXALATE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
LEXAPRO | Capsules | escitalopram oxalate | 5 mg | 021323 | 1 | 2005-08-17 |
LEXAPRO | Capsules | escitalopram oxalate | 10 mg and 20 mg | 021323 | 1 | 2005-03-30 |
US Patents and Regulatory Information for ESCITALOPRAM OXALATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pharm Assoc | ESCITALOPRAM OXALATE | escitalopram oxalate | TABLET;ORAL | 077512-001 | Sep 12, 2012 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Invagen Pharms | ESCITALOPRAM OXALATE | escitalopram oxalate | TABLET;ORAL | 078604-001 | Sep 11, 2012 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Teva Pharms Usa | ESCITALOPRAM OXALATE | escitalopram oxalate | TABLET;ORAL | 076765-003 | Mar 14, 2012 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |